Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DCK | P27707 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875849 | 0.87 | DCK (0.46) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12875931 | 0.82 | ALDH1A1 (0.46) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL1198661 | 0.81 | MEN1 (0.49) | MAPTMEN1ALDH1A1KMT2APPARD | |
| SCHEMBL12875870 | 0.80 | ALDH1A1 (0.44) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12875924 | 0.80 | LMNA (0.54) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12875949 | 0.76 | PPARG (0.41) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12876157 | 0.75 | KLKB1 (0.43) | MAPTALDH1A1LMNAFFAR1PPARD | |
| SCHEMBL1436666 | 0.74 | PPARG (0.48) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL13801071 | 0.73 | ADORA3 (0.59) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL12876150 | 0.72 | FFAR1 (0.36) | MAPTMEN1ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | MAPT 4667/4885MEN1 2661/4885ALDH1A1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.